Patterns Of Care, Survival, and Costs Of Second-Line Treatment In Medicare Beneficiaries With Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2
|
作者：
Danese, Mark
Griffiths, Robert
Gleeson, Michelle
Dalvi, Tapashi
Li, Jingyi
Deeter, Robert G.
Mikhael, Joseph R.
Dreyling, Martin
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2936.2936
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2936
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COMPARATIVE EFFECTIVENESS OF SECOND-LINE IMMUNE TARGETED TREATMENTS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A NETWORK META-ANALYSIS
    Mohamed, A. F.
    Kandikatla, R.
    Yakkala, V. K.
    Solodokin, L.
    Doucette, J.
    Yunusa, I
    Eguale, T.
    VALUE IN HEALTH, 2024, 27 (06) : S34 - S34
  • [32] FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
    Sharma, Poornima
    Kasamon, Yvette L.
    Lin, Xue
    Xu, Zhenzhen
    Theoret, Marc R.
    Purohit-Sheth, Tejashri
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4331 - 4337
  • [33] FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
    Elmacken, Mona
    Peredo-Pinto, Helkha
    Wang, Cong
    Xu, Zhenzhen
    Tegenge, Million
    Jaigirdar, Adnan A.
    Theoret, Marc R.
    Purohit-Sheth, Tejashri
    Kasamon, Yvette L.
    CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2309 - 2316
  • [34] Diffuse large B-Cell Lymphoma (DLBCL) - CHMP recommends Columvi® from second Recurrence
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (03) : 259 - 259
  • [35] Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
    Kambhampati, Swetha
    Saumoy, Monica
    Schneider, Yecheskel
    Serrao, Steve
    Solaimani, Pejman
    Budde, Lihua Elizabeth
    Mei, Matthew G.
    Popplewell, Leslie L.
    Siddiqi, Tanya
    Zain, Jasmine
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Danilov, V. Alexey
    Herrera, Alex F.
    Thiruvengadam, Nikhil R.
    BLOOD, 2022, 140 (19) : 2024 - 2036
  • [36] CLINICAL FEATURES AND SURVIVAL OF PATIENTS WITH LATE RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Castillo-Giron, C.
    Rivas-Delgado, A.
    Dlouhy, I
    Rovira, J.
    Mozas, P.
    Rivero, A.
    Frigola, G.
    Balague, O.
    Baumann, T.
    Correa, J. G.
    Magnano, L.
    Jimenez-Vicente, C.
    Gomez, M.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Gine, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2020, 105 : 291 - 292
  • [37] Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
    Ananth, Snegha
    Kaur, Supreet
    Al-Abayechi, Alaq
    Blaize, Jean Pierre
    Boyle, Lauren Diaz
    Djoumessi, Lakene Raissa Djoufack
    Gutarra, Manuel Espinoza
    Franklin, Kathleen
    Lu, Lindsey
    Lucero, Kana Tai
    Nazarewicz, Phillip
    Pandya, Abhishek
    Souza, Gabriel Roman
    Song, Michael M.
    Warnecke, Brian
    Whitehead, Jennifer
    Williams, Madison H.
    Williams, Ryan A.
    Mader, Michael
    Nooruddin, Zohra
    BLOOD, 2022, 140 : 5195 - 5197
  • [38] Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA
    Morrison, Vicki A.
    Shou, Yaping
    Bell, Jill A.
    Hamilton, Laurie
    Ogbonnaya, Augustina
    Raju, Aditya
    Hennenfent, Kristin
    Eaddy, Michael
    Galaznik, Aaron
    FUTURE ONCOLOGY, 2019, 15 (09) : 1021 - 1034
  • [39] Second Primary Malignancy in Diffuse Large B Cell Lymphoma (DLBCL)
    Ghimire, Krishna B.
    Shah, Binay K.
    BLOOD, 2014, 124 (21)
  • [40] A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
    Cho, Jeong-Yeon
    Jang, Suk-Chan
    Kang, Dong-Won
    Lee, Eui-Kyung
    Koh, Hyein
    Yoon, Dok Hyun
    Park, Mi-Hai
    FRONTIERS IN ONCOLOGY, 2024, 14
12345